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Children  and  adolescents  infected  with  HIV  typically  have  a  lower  response  to  immunization  than  do
those  in  the  general  population.  In  most  developed  countries,  meningococcal  serogroup  C conjugate
vaccine  is one  of the  recommended  vaccines  for such  individuals.  However,  there  have  been no  studies
evaluating  the  antibody  response  to  this  vaccine  in  HIV-infected  children,  adolescents  or young  adults.
In  this  study,  we  evaluated  that  response  using  serum  bactericidal  antibody  (SBA)  and  enzyme-linked
immunosorbent  assay,  comparing  HIV-infected  with  non-HIV-infected  patients,  as  well  as  analysing  the
occurrence  of  side  effects.  In non-responders,  we  assessed  the  antibody  response  to  revaccination.  This
clinical  trial  involved  92  patients  between  10 and  20 years  of  age: 43  HIV-infected  patients  (HIV+  group)
and  49  non-HIV-infected  patients  (HIV−  group).  After  one  dose  of  the  vaccine,  72.1%  of  the  HIV+  group
patients  and  100%  of  the  HIV−  group  patients  were  considered  protected.  Of the  HIV+ group  patients
who  received  a second  dose  of  the  vaccine,  only  40%  acquired  protection.  Overall,  81.4%  of  the  HIV+  group
patients  acquired  protection  (after  one  or  two  doses  of  the  vaccine).  Side  effects  occurred  in  16.3% and
44%  of  the  HIV+  group  and  HIV−  group  patients,  respectively.  Therefore,  the  meningococcal  serogroup  C
conjugate  vaccine  proved  to  be safe  and  effective  for  use  in  HIV-infected  children,  adolescents,  and  young
adults,  although  their  antibody  response  was  weaker  than  that  shown  by non-HIV-infected  patients.  This
indicates  the  need  to discuss  changes  to  the  immunization  schedule  for children,  adolescents,  and  young
adults  infected  with  HIV,  in order  to  ensure  more  effective  protection  against  meningococcal  disease.. Introduction
In childhood and adolescence, AIDS typically presents with
evere humoral immune dysfunction related to infections caused
y encapsulated bacteria, such as Neisseria meningitidis, Streptococ-
us pneumoniae, and Haemophilus inﬂuenzae [1,2]. Studies indicate
hat the incidence of bacterial meningitis is higher in AIDS patients
han in the general population. This might be directly related to
D4 count, given that the risk of developing bacterial meningitis is
lready 40–50 times greater in HIV-infected adults with CD4 counts
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above 200 cells/mm3, whereas it is 400 times greater in those
with CD4 counts below 200 cells/mm3 [3]. The etiology of bacterial
meningitis is most often related to meningococcal or pneumococcal
disease [3]. Infection with HIV has been implicated as a risk factor
for the development of and mortality from meningococcal disease
[4,5].
One of the pillars of HIV treatment is the use of vaccines for
preventable diseases. It is known that routine immunization is less
efﬁcient in HIV-infected individuals than in the general population.
The damage caused by HIV is associated with fairly constant viral
replication and has a major effect on the immunological memory
elicited by vaccines. In general, the immunization of HIV-infected
individuals is safe and beneﬁcial, with few side effects, although live
Open access under the Elsevier OA license.virus or bacteria vaccines should be used with caution in severely
immunocompromised individuals [6,7].
Meningococcal serogroup C conjugate vaccine is frequently rec-
ommended for HIV-infected children and adolescents, in Brazil and
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any other countries [8–10]. Its immunogenicity is extremely high
>95%) in immunocompetent populations [11–13]. Previous clinical
tudies involving non-HIV-infected populations of immunocom-
romised individuals have shown variable responses to vaccines,
epending on the existing degree of immunosuppression [14–18].
There  have been no studies evaluating the speciﬁc efﬁcacy of
he meningococcal serogroup C conjugate vaccine, when used in
solation, in AIDS patients. A recent study of the use of the quadri-
alent meningococcal conjugate vaccine (against serogroups A, C, Y,
nd W135) showed a 52% response to serogroup C in HIV-infected
ndividuals [19]. Although the use of the quadrivalent vaccine is
ecommended in the United States, the only meningococcal con-
ugate vaccine available in Brazil and in most other countries is
hat against serogroup C. Although the use of the meningococ-
al serogroup C conjugate vaccine is recommended in guidelines
or the treatment of pediatric HIV/AIDS, there are as yet no data
egarding its effectiveness. Therefore, the investigation of its use
n children and adolescents with AIDS might provide information
bout the response to this vaccine, as well as its potential for pre-
enting meningococcal disease.
The main objective of this study was to evaluate the antibody
esponse to the meningococcal serogroup C conjugate vaccine in
IV-infected children, adolescents, and young adults. Additional
bjectives included determining whether the immunity acquired
orrelated with clinical, viral, and immunological parameters of
nfection; analysing the response to a second dose of the vaccine,
f necessary; and reporting any side effects of the vaccine.
.  Methods
.1. Study design
This  was a prospective clinical trial involving a cumulative sam-
le of HIV-infected children, adolescents, and young adults (HIV+
roup) and age-matched non-HIV-individuals (HIV− group). The
ample size was calculated considering an expected rate of 60% of
ubjects with a post-vaccination serum bactericidal antibody (SBA)
iter ≥8, assuming an actual proportion of 90%. To compensate for
 potential loss of 20%, we selected 40 subjects for inclusion in each
roup. The method employed was hypothesis testing for comparing
wo proportions [20].
All  subjects were recruited among patients treated at the Insti-
uto da Crianc¸ a do Hospital das Clínicas da Universidade de São
aulo, Department of Pediatric Infectious Diseases – Brazil or at
he Centro de Referência e Treinamento em DST/Aids - Programa
stadual São Paulo – Brazil, both located in the city of São Paulo,
razil. Patients were considered eligible if they were between 10
nd 20 years of age, had never been vaccinated with meningococcal
erogroup C conjugate vaccine, had no prior history of meningococ-
al disease or meningitis of undetermined etiology, had not used
orticosteroids at immunosuppressive doses, had not been treated
ith immunosuppressive therapy or chemotherapy, and presented
ith no evidence of signiﬁcant dyslipidemia [21]. The inclusion cri-
eria for the HIV+ group were being HIV-infected, having a CD4
ount ≥100 cells/mm3, and not having received immunoglobulin
herapy within the last six months. The inclusion criterion for the
IV− group was having no underlying disease that would result in
mmunosuppression or would require immunosuppressive ther-
py. The HIV− group patients with unknown HIV serologic status
ere submitted to a rapid HIV test to conﬁrm that status.
We  collected demographic, clinical, viral and immunologicalata at inclusion. All patients underwent an initial blood test to
etermine pre-vaccination SBA titers, after which they were vac-
inated with the meningococcal serogroup C conjugate vaccine in
solation (i.e., no other vaccine was administered). Patients were30 (2012) 5482– 5486 5483
submitted  to a second blood test within 30 days after the vacci-
nation (allowing the comparison of pre- and post-vaccination SBA
titers). In addition to the immune response, side effects related to
the vaccine were also analyzed.
Patients who did not reach the antibodies levels that are consid-
ered protective in healthy populations (the only data available, as
there are no speciﬁc data regarding the HIV-infected population)
after the initial dose of the vaccine were indicated for a second dose.
In those cases, additional blood samples were collected prior to and
following the second dose vaccination [11,12].
The meningococcal serogroup C conjugate vaccine used in this
study was CRM197 (conjugated meningococcal C oligosaccharide-
CRM197, a protein of Corynebacterium diphtheriae; Chiron/Novartis
Vaccines, Siena, Italy). The vaccine was procured and provided by
the Brazilian National Ministry of Health.
The study was approved by the research ethics committees
of both participating institutions. Written informed consent was
obtained from the young adult patients or, for children and adoles-
cents, from their parents or legal guardians.
2.2. Laboratory testing
Enzyme-linked immunosorbent assay (ELISA) and SBA were
performed according to previously described protocols [22–25].
In some speciﬁc populations and in patients at risk for certain
conditions, such as meningococcal disease, serologic markers are
used in order to determine vaccine effectiveness. The internation-
ally accepted serologic correlate of protection against infection
(the gold standard) in healthy individuals is an SBA titer ≥4 when
human-derived complement is used or an SBA titer ≥8 when baby
rabbit complement is used [26–29]. Some authors have stated that
the post-vaccination SBA titer should be ≥128, or a 4-fold increase
over the pre-vaccination SBA titer [29,30]. Another way to conﬁrm
acquired immunity is by identifying a substantial post-vaccination
increase in the titles of meningococcal serogroup C anticapsular
antibodies, as measured by ELISA, with the minimum acceptable
concentration (minimum level considered to be protective) being
2 g/ml [31–34].
Because  this study involved immunocompromised patients, we
established minimum acceptable levels of protection: an SBA titer
≥8 with baby rabbit complement (Pel-Freez Biologicals, Rogers, AR,
USA) and control sera (CDC1992, Centers for Disease Control and
Prevention [CDC], Atlanta, GA, USA); and a 4-fold increase over the
pre-vaccination SBA titer. We  analyzed the statistical difference
between the pre- and post-vaccination ELISA antibody concen-
trations, considering the minimum acceptable post-vaccination
concentration of 2 g/ml. Patients who  received a second dose of
the vaccine were evaluated using the same criteria.
2.3. Statistical analysis
The  ELISA and SBA results and their respective 95% conﬁdence
intervals (95% CIs) were expressed as geometric mean concentra-
tions (GMC) and geometric mean titers (GMT). The relationship
between those titers and variables such as clinical and laboratory
HIV, were evaluated with Chi-square test (2) or Fisher’s exact test,
as appropriate.
Comparisons between the two groups in terms of the ELISA
and SBA results were performed by Student’s t-test or the
Mann–Whitney test. Mean pre- and post-vaccination titers (ELISA
and SBA) were compared by paired Student’s t-test or the Wilcoxon
test. Intragroup differences between pre- and post-vaccination
values were considered statistically signiﬁcant at a level of 5%.
In addition, a difference between two  groups of similar size and
similar variance whose 95% CIs do not overlap was considered
5484 D.V.  Bertolini et al. / Vaccine 30 (2012) 5482– 5486
Table 1
Response to vaccination with meningococcal serogroup C conjugate vaccine in HIV-infected and non-HIV-infected children, adolescents, and young adults.
Variable Group p-Value
HIV-infected (n = 43) Non-HIV-infected (n = 49)
SBA titer
Pre-vaccination, GMT  (95% CI) 19.95 (4.48–35.43) 39.96 (13.09–66.83) 0.081a
Post-vaccination, GMT (95% CI) 500.33 (266.51–734.14) 2873.47 (2019.10–3727.73) <0.001a
ELISA (g/ml)
Pre-vaccination, GMC  (95% CI) 0.86 (0.36–1.36) 2.27 (1.26–3.29) 0.004a
Post-vaccination, GMC (95% CI) 9.86 (4.75–14.97) 18.71 (11.98–25.42) 0.001a
SBA titer
Pre-vaccination
≥8,  n (%) 7 (16.3) 17 (34.7) 0.032b
Post-vaccination
≥8, n (%) 35 (81.4)  49 (100.0) NA
Increase  over baseline
≥4-fold,  n (%) 31 (72.1) 49 (100.0) NA
Response  to vaccine
Yes,  n (%) 31 (72.1) 49 (100.0) NA
Side  effects
Yes,  n (%) 7 (16.3) 22 (44.0) 0.004b
SBA: serum bactericidal antibody; GMT: geometric mean titer; CI: conﬁdence interval; ELISA: enzyme-linked immunosorbent assay; GMC: geometric mean concentration;
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a Mann–Whitney Test.
b Chi-square test.
igniﬁcant at a level of approximately 5%, thus enabling signiﬁcant
ifferences between groups to be assessed by non-overlapping CIs.
Chi-square tests (2) or Fisher’s exact tests were used to com-
are the groups in terms of the proportions of patients with SBA
iters ≥8, patients showing a 4-fold rise in SBA titers, patients
ho responded to the vaccine, and patients who experienced side
ffects.
The remaining variables of the study, including sociodemo-
raphic and clinical variables, were analyzed by descriptive
tatistics – mean (standard deviation) or median (minimum and
aximum) – when quantitative and by proportions when qualita-
ive.
A level of signiﬁcance of 5% was considered for all statistical
ests. The statistical software used in all analysis was the Statistical
ackage for the Social Sciences, version 14.0 (SPSS Inc., Chicago, IL,
SA).
. Results
.1. Patients
We  included a total of 92 individuals in the study (mean
ge = 13.9 years, range 10–19 years), from May  to December
009: 43 in the HIV+ group (mean age = 13.8 years; range
0–19 years); and 49 in the HIV− group (mean age = 13.9 years;
ange 10–19 years). In the sample as a whole and in each of the two
roups, 52.7% of the patients were female and 47.3% were male.
ll of the patients in the HIV+ group were under treatment with
ighly active antiretroviral therapy (HAART). There were no losses
n either of the study groups.
.2.  Response to meningococcal vaccine
As shown in Table 1, the mean level of post-vaccination response
as higher in the HIV− group than in the HIV+ group, whether
valuated by ELISA (p = 0.001) or by SBA (p < 0.001). The differences
etween groups are evidenced by the non-overlapping 95% CIs.
Before  vaccination, the percentage of patients with SBA titers
8 was higher in the HIV− group than in the HIV+ group (34.7% vs.
6.3%). There were signiﬁcant differences between the two groups
n terms of these titers (Table 1). In the HIV+ group, 35 (81.4%) of the
atients had a post-vaccination SBA titer ≥8, compared with 100%of  those in the HIV− group. A 4-fold increase in the SBA titer after
vaccination was observed in 31 (72.1%) of the HIV+ group patients,
again compared with 100% of those in the HIV− group (Table 1).
We deﬁned a positive antibody response to the vaccine as
the combination of the established protective criteria (a post-
vaccination SBA titer ≥8 and a 4-fold increase over the initial titer).
Of the 43 HIV+ group patients, 31 (72.1%) had a positive response
and were considered protected, whereas 12 (27.9%) did not respond
and were considered unprotected (Table 1). In the HIV− group,
100% of the patients acquired protection with a single dose of the
vaccine. In the HIV+ group, 30 patients had post-vaccination ELISA
levels >2 g/ml, and 31 showed a 4-fold increase over the initial SBA
titer. The only case in which there was  no concordance between
the two tests had a SBA titer close to the protection limit. There-
fore, revaccination was  recommended to all 12 patients who were
considered unprotected.
In  the HIV+ group, the antibody response was  not found to
be signiﬁcantly associated with clinical variables or with the
results of viral and immunological tests. Responders and non-
responders presented the same clinical proﬁle (CDC classiﬁcation B
and C), immunological proﬁle (absolute CD4 count >350 cells/mm3;
proportion >25%), and virological proﬁle (viral loads below the
detection limit in most cases). None of the patients experienced
treatment failure during the study period.
3.3. Pre- and post-vaccination antibody levels
Comparing pre- and post-vaccination SBA titers, we  found that
there was  an increase in the mean SBA titer in both groups (Table 1).
The differences between the pre- and post-vaccination SBA were
statistically signiﬁcant for both groups (p < 0.001; Wilcoxon test).
The same was true for the pre- and post-vaccination ELISA levels
(p < 0.001; Wilcoxon test). Those differences are also evidenced by
the non-overlapping 95% CIs.
The two  groups were comparable in terms of the mean pre-
vaccination SBA titer (p = 0.08). However, as shown in Table 1,
the mean pre-vaccination ELISA level was signiﬁcantly higher in
the HIV− group than in HIV+ group (p = 0.004). The mean post-
vaccination SBA titer was  signiﬁcantly higher in the HIV− group
than in HIV+ group (2873.47 vs. 500.33; p = <0.001), as was the
mean post-vaccination ELISA level (18.71 vs. 9.86; p = 0.001). We
D.V. Bertolini et al. / Vaccine 
Table  2
Side  effects of vaccination with meningococcal serogroup C conjugate vaccine in
HIV-infected and non- HIV-infected children, adolescents, and young adults.
Side effects Group
HIV-infected
(n = 7)
Non-HIV-infected
(n = 22)
Pain 5 20
Pain and fevera 0 1
Pain,  erythema, and induration 0 1
Pain  and myalgia 1 0
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tPain  and diarrhea 1 0
a Fever deﬁned as an axillary temperature ≥37.8 ◦C.
lso observed differences between the two groups in terms of the
agnitude of the response (Table 1).
.4. Response to revaccination
As  previously mentioned, 12 HIV+ group patients did not acquire
rotection after the ﬁrst dose of the vaccine. However, only 10 of
hese patients received the second dose. One patient was excluded
ecause she was pregnant at this stage of the study, and another
bandoned the protocol.
After  the second dose of the meningococcal serogroup C conju-
ate vaccine, only 4 of the 10 patients showed a positive immune
esponse, achieving the established minimum protection (≥ a 40%
esponse to the revaccination). In 5 of the 10, the titer remained
nchanged. One of the non-responders showed a slight (2-fold) rise
n the SBA titer. Only 4 of the 10 patients attained ELISA antibody
evels >2 g/ml after the second dose of the vaccine.
We  found that the magnitude of the SBA GMT  was
reater after the ﬁrst dose of the vaccine than after the sec-
nd: mean, 690.6 ± 820.9 vs. 56.0 ± 16.0; and median, 512.0
32.0–4096.0) vs. 64.0 (32.0–64.0). The mean time between the
wo doses of the vaccine was 347.3 ± 68.5 days—median, 312.0 days
259.0–458.0 days).
The overall antibody response in HIV-infected patients receiv-
ng one or two doses of the meningococcal serogroup C conjugate
accine was 81.4% (35 of the 43 patients evaluated). Of the 35
esponders, 31 had received a single dose and 4 had received two
oses.
.5. Side effects
As  shown in Table 1, after the ﬁrst dose of the vaccine, side effects
ere observed in 16.3% of the HIV+ group patients and in 44% of the
IV− group patients (p = 0.004). The reported side effects are shown
n Table 2. No side effects were reported among the 10 patients who
eceived a second (booster) dose of the vaccine.
. Discussion
In the present study, 72.1% of the HIV-infected patients evalu-
ted were responsive to a single dose of meningococcal serogroup
 conjugate vaccine (as is usually recommended), and this rate
ncreased to 81.4% when those receiving a second dose were
ncluded. However, 100% of the non-HIV-infected patients achieved
rotective levels after receiving the ﬁrst dose, a result that is
onsistent with those of other studies involving healthy children
r adolescents [35–38]. The magnitude of the antibody response
btained was signiﬁcantly smaller in the HIV-infected patients than
n the non-HIV-infected patients.
The differences found were expected, given the results of stud-
es of the use of other vaccines in HIV-infected patients. In general,
he response to vaccination was weaker in HIV-infected patients30 (2012) 5482– 5486 5485
than  in those not so infected. However, the response obtained in
the present study was  signiﬁcant for the prevention of meningo-
coccal disease in such a susceptible population. It is of note that
two doses provided better results than did a single dose. These
results are in accordance with a recent publication of the Advisory
Committee on Immunization Practices of the Centers for Disease
Control and Prevention and the American Academy of Pediatrics,
which recommends an immunization schedule with two doses of
the quadrivalent conjugate vaccine (serogroups A, C, Y, and W135)
for HIV-infected patients [39]. Nevertheless, in our study only 40%
of the HIV-infected patients who  were revaccinated responded
to the booster dose, possibly due to immune system dysfunction
caused by the HIV. It is debatable whether the interval between the
two  doses inﬂuenced the response in those patients. Further stud-
ies, with shorter intervals between doses, are needed in order to
evaluate such aspect.
We  found that the antibody response in HIV-infected patients
did not correlate with clinical variables or with the results of
viral and immunological tests. Therefore, the responders and non-
responders presented the same proﬁle: CDC classiﬁcation B and
C; absolute CD4 count >350 cells/mm3 (with a proportion >25%);
and viral loads below the detection limit in most cases. The HIV+
group showed very similar characteristics since the beginning, but
no sample was calculated to determine the associations between
those variables. Therefore, we were unable to identify a group with
potential characteristics for a worse response to vaccine. This can
be considered a limitation of this study. In a recent study, Siberry
et al. evaluated the quadrivalent meningococcal conjugate vac-
cine in HIV-infected patients [19]. The authors found that CD4
counts and HIV viral loads correlated with the immune response
achieved after vaccination. However, unlike our study, in which a
CD4 count <100 cells/mm3 was  an exclusion criterion, that study
did not exclude patients with low CD4 counts.
We found a statistically signiﬁcant difference between the HIV-
infected and non-HIV-infected patients in terms of the side effects
of the meningococcal serogroup C conjugate vaccine, which were
more common in the non-HIV-infected patients. No serious side
effects were observed in either group, indicating that the vaccine is
safe, as reported in prior studies [26]. One explanation for the fact
that HIV-infected patients reported fewer side effects is that these
patients are often submitted to medical procedures, such as blood
draws and vaccinations, and might therefore be more tolerant to
pain, myalgia, and other symptoms.
In conclusion, the meningococcal serogroup C conjugate vaccine
was found to be effective for HIV-infected children, adolescents,
and young adults, although the antibody response obtained was
weaker than that obtained in the non-HIV-infected patients.
Knowledge of this response could suggest the need to alter the
immunization schedule for HIV patients in these age groups,
probably by adding a booster dose of meningococcal vaccine,
thus ensuring more effective protection against meningococcal
disease.
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